Amylyx Pharmaceuticals Inc (AMLX) Stock Price, Quote & News

Company Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fix...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 682 0917

Website: amylyx.com

Address:

43 Thorndike Street, Cambridge, United States

SilentBull69 Feb. 25 at 3:46 AM

$NCLH $CCL $AMLX $JBLU Great State of the Union addressed by President Trump And if you noticed, not one demorat would stand up when the young sons and daughters of American families were being observed after being slain by vicious repeat offenders that were constantly released back into society by radical left-wing Demorat judges Not one Demorat stood up when Trump was pressing the importance of passing legislation for Voter ID and proof of citizenship, to prevent stolen elections, as Omar kept yelling Not one Demorat stood up when Trump was talking about laws to be passed to eliminate transgender surgery on minors and ending wars It is a very sad when you’ve got an entire political party in this country that is so anti-American I’m grateful for Trump as IMO he is by far the best President of my lifetime and I am in my 60s God Bless America and all of our fallen sons and daughters who deserved happy lives, but are no longer with us Best Wishes to ALL good virtuous people ❤️

2 · Reply

OfficialStocktwitsUser Feb. 22 at 2:12 PM

$AMLX RSI: 47.18, MACD: 0.0656 Vol: 0.61, MA20: 14.39, MA50: 13.48 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Doozio Feb. 21 at 6:36 PM

$AMLX 👀 MAMA 3wt. N they ain’t gonna BRAG. No faatch 💣s 🐒🍌🧠⏰♾️

0 · Reply

ajmore Feb. 20 at 3:25 PM

$AMLX the target prices going up, as explaibed before👇

0 · Reply

erevnon Feb. 20 at 2:44 PM

B of A Securities maintains Amylyx Pharmaceuticals $AMLX at Buy and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

neuroinvestor3 Feb. 20 at 2:43 PM

$AMLX https://www.biospace.com/fda/its-official-fda-will-now-default-to-one-clinical-trial-for-drug-applications

0 · Reply

ajmore Feb. 20 at 12:58 PM

$AMLX BoFA raise target to 19 from 15!

0 · Reply

ajmore Feb. 19 at 1:49 PM

$AMLX Mizuho raise target from 18 to 19.

1 · Reply

SuperGreenToday Feb. 17 at 11:11 AM

$AMLX Share Price: $14.13 Contract Selected: Jun 18, 2026 $18.0 Calls Buy Zone: $0.84 – $1.04 Target Zone: $1.45 – $1.77 Potential Upside: 63% ROI Time to Expiration: 120 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

LoveRetailFroth Feb. 13 at 2:34 PM

$RXRX Good Morning ☕️ $AMLX $RARE $SANA

0 · Reply

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Jan 29, 2026, 5:05 PM EST - 27 days ago

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Jan 8, 2026, 7:00 AM EST - 6 weeks ago

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

Dec 5, 2025, 9:00 AM EST - 2 months ago

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

Dec 3, 2025, 7:53 PM EST - 3 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 13, 2025, 2:40 PM EST - 3 months ago

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Nov 6, 2025, 2:06 PM EST - 3 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 4 months ago

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Oct 30, 2025, 9:00 AM EDT - 4 months ago

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 27, 2025, 12:20 PM EDT - 4 months ago

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 16, 2025, 4:40 PM EDT - 4 months ago

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

Sep 10, 2025, 12:06 AM EDT - 6 months ago

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Sep 9, 2025, 4:01 PM EDT - 6 months ago

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 8, 2025, 9:01 PM EDT - 6 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 6:14 PM EDT - 6 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 27, 2025, 7:28 AM EDT - 6 months ago

Amylyx to stop development of rare brain disorder drug after trial failure

Aug 27, 2025, 7:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Aug 26, 2025, 9:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 7, 2025, 10:35 PM EDT - 7 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 9:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 21, 2025, 4:26 PM EDT - 7 months ago

Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential

Jul 14, 2025, 2:15 PM EDT - 8 months ago

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

Jul 13, 2025, 5:00 PM EDT - 8 months ago

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Jul 8, 2025, 7:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

Jun 24, 2025, 2:59 PM EDT - 8 months ago

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market

Jun 17, 2025, 10:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 15, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

Jun 12, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

Jun 8, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Jun 3, 2025, 7:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Jun 1, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

May 29, 2025, 10:05 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

May 27, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

May 25, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 21, 2025, 7:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 12, 2025, 7:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

May 11, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

May 10, 2025, 11:19 AM EDT - 10 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

May 8, 2025, 7:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025, 8:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

May 4, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out

May 1, 2025, 9:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

SilentBull69 Feb. 25 at 3:46 AM

2 · Reply

OfficialStocktwitsUser Feb. 22 at 2:12 PM

0 · Reply

Doozio Feb. 21 at 6:36 PM

$AMLX 👀 MAMA 3wt. N they ain’t gonna BRAG. No faatch 💣s 🐒🍌🧠⏰♾️

0 · Reply

ajmore Feb. 20 at 3:25 PM

$AMLX the target prices going up, as explaibed before👇

0 · Reply

erevnon Feb. 20 at 2:44 PM

B of A Securities maintains Amylyx Pharmaceuticals $AMLX at Buy and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

neuroinvestor3 Feb. 20 at 2:43 PM

$AMLX https://www.biospace.com/fda/its-official-fda-will-now-default-to-one-clinical-trial-for-drug-applications

0 · Reply

ajmore Feb. 20 at 12:58 PM

$AMLX BoFA raise target to 19 from 15!

0 · Reply

ajmore Feb. 19 at 1:49 PM

$AMLX Mizuho raise target from 18 to 19.

1 · Reply

SuperGreenToday Feb. 17 at 11:11 AM

0 · Reply

LoveRetailFroth Feb. 13 at 2:34 PM

$RXRX Good Morning ☕️ $AMLX $RARE $SANA

0 · Reply

TalkMarkets Feb. 13 at 11:47 AM

Coya Therapeutics Stock Poised To Appreciate As Company Advances Superior ALS Therapy $PFE $SNY $MTZPY $AMGN $AMLX https://talkmarkets.com/content/stocks--equities/coya-therapeutics-stock-poised-to-appreciate-as-company-advances-superior-als-therapy?post=557175&userid=166882

0 · Reply

ajmore Feb. 11 at 4:56 PM

$AMLX and to add, as i commented before, from trial design and the stage of the trial, patterns observed in the randomised group and on the none-randomised group should be gettinf more consistent making conclusions less prone to errors.

0 · Reply

ajmore Feb. 11 at 4:54 PM

$AMLX what does open label extension (ole) mean? the patients in trial can receive the real drug after their course in trial (placebo or real) has ended. So with the avexitide p3 trial, we would expect around 50 out of the 75 planned participants to be at this stage and as they are also monitored real time using cgm, data sent real time to ... amylyx... a lot of info is getting clearer and the phase 3 is getting de-risked as the analyst commented.

0 · Reply

ajmore Feb. 11 at 4:36 PM

$AMLX single seller, prob short seller, that didnt read the analysts note properly and what does it mean and didnt check whats the real short. Here's a hint, and you would see this when going over the avexitise p3 trial design: The data from the cgm connected to the patients taking part are sent in real time, yes!

0 · Reply

LoveRetailFroth Feb. 10 at 2:30 PM

$AMLX Good Morning ☕️ $RXRX $SANA $RARE

0 · Reply

ajmore Feb. 10 at 12:53 PM

$AMLX Wainwright analyst writes " ...the firm's review of Lucidity trial design shows a structurally de-risked path to approval. "

1 · Reply

ajmore Feb. 10 at 11:29 AM

$AMLX Wainwright raise price target to 28 (from 20).

0 · Reply

SilentBull69 Feb. 5 at 6:04 PM

$AMLX Shorting should be illegal, especially naked shorting and yeah, we know that parts are already legal, but no one enforces it in the SEC

0 · Reply

ajmore Feb. 5 at 12:03 PM

$AMLX shares surrendered and not sold! thats for paying tax that US charges on their holdings.

1 · Reply

BillionerOfKing Feb. 4 at 10:12 PM

$AMLX Current Stock Price: $13.89 Contracts to trade: $14.0 AMLX Feb 20 2026 Call Entry: $1.24 Exit: $1.65 ROI: 33% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SilentBull69 Feb. 4 at 5:32 PM

$AMLX WTF Four officers.. two of which are listed as a director have all sold shares in the last few days Once sold last week as well, claiming it was for money to pay tax obligations so what’s going on?

1 · Reply

SectorRotate Feb. 4 at 1:51 PM

$AMLX is a clinical-stage biotech developing therapies for Alzheimer's and other neurological diseases; it is in a high-failure-risk therapeutic area and is years away from potential approval.

1 · Reply

Market Cap	1.62B
Revenue (ttm)	87.37M
Net Income (ttm)	-301.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-345.36%
Debt to Equity Ratio	0.00

Volume	592,100
Avg Vol	1,498,616
Day's Range	N/A - N/A
Shares Out	109.82M
Stochastic %K	55%
Beta	-0.31
Analysts	Strong Sell
Price Target	$21.67